Celularity (CELU) and Antengene Collaborate to Evaluate Potential Therapeutic Synergy of Combining Antengene’s Leading Bispecific Antibody with Celularity’s Natural Killer Cel
Receive instant alerts when news is published about your stocks. Claim your one week free trial for StreetInsider Premium here.
Antengene Corporation Limited today announced that it has entered into a preclinical research collaboration with Celularity Inc. (NASDAQ: CELU). Antengene and Celularity will evaluate the potential therapeutic synergy combining Antengene’s bispecific antibody with the natural killer (NK) cell therapy platform derived from cryopreserved human placental hematopoietic stem cells.
Dr. Jay Mei, Founder, Chairman and CEO of Antengene, said: “The evaluation of new technologies that have the potential to improve cancer care, either as monotherapy or in synergistic combination with programs, is essential to Antengene’s mission. After careful and comprehensive evaluation, Antengene is very pleased to initiate its first research collaboration in the important field of cellular medicine with Celularity.”
Dr. Mei continued, “Celularity’s proprietary, novel, allogeneic, cryopreserved, off-the-shelf cell medicine platform is very exciting for Antengene. We look forward to collaborating with the company to explore the potential synergies of combining bispecific antibodies and Celularity’s experimental NK cell therapy programs, together or in combination with other agents such as antibodies that target tumor associated antigens. (TAA). We hope that this collaboration will lead to potential new combination therapies that will improve the treatment of patients with hematological cancers and solid tumors.
Dr. Bo Shan, Chief Scientific Officer of Antengene, said, “We are delighted to partner with Celularity’s NK cell platform. The rationale for our collaboration rests on two assumptions, formed from a preclinical and clinical research base. First, that our bispecific antibody, potentially activating NK cells upon cross-linking of immune checkpoint inhibitors (ICI) in the tumor microenvironment (TME), can synergize with TAA antibodies to enhance anti-tumor response Second , that our bispecific antibody can enhance NK cell proliferation and increase their persistence in the TME.”
Robert J. Hariri, MD, Ph.D., Founder, President and CEO of Celularity, added, “We are excited to enter into this research collaboration with Antengene to forge novel therapeutic strategies for solid tumors. and hematological malignancies using our placenta-derived cell therapy platform. There is immense potential to combine two novel approaches to improve tumor targeting while enhancing allogeneic NK cell activation and activity in the tumor microenvironment. This strategy can identify new therapeutic options targeting a wide range of cancers.